The combination of vemurafenib and cobimetinib in advanced melanoma
View/ Open
Date
2016-11-01ICR Author
Author
Spain, L
Goode, E
McGovern, Y
Joshi, K
Larkin, J
Type
Journal Article
Metadata
Show full item recordCollections
Subject
Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
Vemurafenib
cobimetinib
advanced melanoma
BRAF mutation
MAPK pathway
BRAF-MUTATED MELANOMA
RANDOMIZED CONTROLLED-TRIAL
FREE SURVIVAL PFS
METASTATIC MELANOMA
MEK INHIBITION
OPEN-LABEL
POSITIVE MELANOMA
MUTANT MELANOMA
RAF INHIBITION
RESISTANCE
Research team
Melanoma and Kidney Cancer
Language
eng
License start date
2016-11-01
Citation
EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (11), pp. 1105 - 1111 (7)
Publisher
TAYLOR & FRANCIS LTD
Related items
Showing items related by title, author, creator and subject.
-
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy, OJ; Kicinski, M; Valpione, S; Gandini, S; Suciu, S; et al. (ELSEVIER SCI LTD, 2022-04-01)BACKGROUND: β-adrenergic receptors are upregulated in melanoma cells and contribute to an immunosuppressive, pro-tumorigenic microenvironment. This study investigated the prognostic and predictive value of β-adrenoreceptor ... -
Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.
Siddiqui, MS; Lai, ZM; Spain, L; Greener, V; Turajlic, S; et al. (SPRINGER, 2020-05-24)PURPOSE: Ipilimumab, a monoclonal antibody inhibiting CLTA-4, is an established treatment in metastatic melanoma, either alone or in combination with nivolumab, and results in immune mediated adverse events, including ... -
Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.
Bol, KF; van den Bosch, T; Schreibelt, G; Mensink, HW; Keunen, JEE; et al. (2016-10)